Singapore study shows shorter people are at higher risk of novel coronavirus-IT & Health-cnBeta.COM



[ad_1]

According to the foreign media BGR,A new study found that due to the downward trajectory of the droplets, short people are at higher risk of contracting the new coronavirus.This research was recently published in the peer-reviewed journal Fluid Physics. A new physical simulation by Singapore researchers demonstrates this and shows that, under other conditions, short people are more likely to be infected with the new coronavirus than tall people.

access:

The first wave of Tmall Double 11 will open 14 million products in the early morning of November 1, open discount mode

JD Double Eleven coupon entry: the top three home games will be discounted at 40 for every 300 or so, and Jingxiang’s red envelope is up to 1,111 yuan

5.0026360.figures.online.f1.jpeg

This study set out to measure the spread of droplets containing the new coronavirus when coughing in an outdoor environment. Studies have found that, in suitable wind conditions, the propagation distance of large droplets can reach 21 feet and, if the air is dry, it can spread even further. At the same time, for a much smaller drop, the possible distance of propagation can reach one meter.

The report also noted that larger droplets tend to “settle quickly due to gravity,” while smaller droplets tend to linger in the air for longer. Trapped droplets will naturally increase the chance that nearby uninfected people will be exposed to the virus. On the contrary, if the infected person is short, tall people can also provide some degree of protection. On the contrary, if you are short and have a tall person who is infected with the coronavirus, the possibility of transmission will increase.

5.0026360.figures.online.f4.jpeg

The study stated:

Based on a typical downward cough trajectory, teens and children may be at higher risk than adults. It is recommended that short young people and adults maintain a social distance of more than 2 meters from tall people. Surgical masks can effectively capture large droplets, so it is recommended to use them when necessary.

5.0026360.figures.online.f5.jpeg

At the same time, the recent epidemic situation in most states in the United States is dire. Last weekend, the number of new cases of newly diagnosed crowns in the United States soared to 126,000 in a single day. At the same time, the infection rate of the new coronavirus in the United States has increased by almost 60% in the last two weeks alone.

Looking ahead, experts warn that cold weather will make things worse. One of the reasons behind this warning is that the new coronavirus spreads more easily in colder air environments. Studies have shown that when the air is cold and dry, the new coronavirus droplets remain in the air longer. This, in turn, increases the likelihood that someone will be exposed to the virus.

Among the worrying statistics about the new coronavirus, the only good news is that Pfizer announced that a candidate vaccine they have been studying may be 90% effective.

Some of the highlights from Pfizer’s press release include:

In the first interim efficacy analysis, without any prior evidence of SARS-CoV-2 infection, the candidate vaccine was more than 90% effective in preventing participants from contracting COVID-19;

Analysis and evaluation of 94 confirmed COVID-19 cases among trial participants;

A total of 43,538 study participants were recruited, of whom 42% had different backgrounds and no serious safety concerns were observed; safety data and other efficacy data are still being collected;

An Emergency Use Authorization (US) is scheduled to be submitted to the US Food and Drug Administration (FDA) shortly after the required safety milestones are reached, which is currently expected to take place in the third week of November;

Clinical trials will continue until the final analysis of the 164 confirmed cases to collect more data and determine the performance of the candidate vaccine relative to other research endpoints.

If all goes according to plan, the company plans to produce 50 million doses of vaccine by the end of 2020 and 1.3 billion doses of vaccine in 2021.

[ad_2]